Table 3.

Proportions of the surveyed patients with msPsO and dermatologists reporting treatment discontinuation reasons for traditional oral treatments and biologic treatments

	Patients with msPsO		Dermatologists
	N	%	N	%
Treatment discontinuation reasons for traditional oral treatments
Unsatisfactory treatment effects	197	77.2	50	92.0
Treatment side effects	197	33.0	50	92.0
Treatment safety concern	197	29.9	50	78.0
Patients considering the disease as cured	197	5.6	50	44.0
Pregnancy preparation	197	4.6	50	86.0
Drug interactions	197	0.0	50	68.0
Breastfeeding	197	0.0	50	70.0
Treatment discontinuation reasons for biologic treatments
Loss of treatment effects over time	133	60.9	50	76.0
Primary treatment failure	133	24.1	50	54.0
Paradoxical skin reactions	133	9.0	50	60.0
Financial difficulties	133	6.8	50	66.0
Treatment side effects	133	5.3	50	44.0
Limited treatment access	133	4.5	50	24.0
Pregnancy preparation	133	3.8	50	70.0
Treatment inconvenience	133	3.8	50	36.0
Needle fear	133	2.3	50	14.0
Patients considering the disease as cured	133	1.5	50	62.0
Injection site reactions	133	0.8	50	56.0
Drug interactions	133	0.8	50	26.0
Deteriorating comorbidities	133	0.8	50	62.0
Breastfeeding	133	0.8	50	58.0

msPsO moderate-to-severe psoriasis, SD standard deviation